At the Heart of Cardiovascular Disease Prevention 2024

6th Annual Evening Dinner Symposium
May 2, 2024
Image
patients with doctor smiling
05/02/2024 17:00
Days
Hours
Mins
Secs

Until At the Heart of Cardiovascular Disease Prevention 2024 Begins

Details

This evening dinner symposium will educate physicians, advanced care providers and the broader healthcare team on current guidelines and opinion on the identification of risk factors, prevention measures and treatment options for cardiovascular disease. Registration fees starting at $75.00

Date & Time: Thursday May 2, 2024 | 5:00pm - 8:30pm
Location: Brackett's Crossing Country Club | 17976 Judicial Rd, Lakeville, MN 55044

This ACCME-accredited evening symposium brings together healthcare professionals and their care teams to learn about the latest in cardiovascular disease prevention. Our 2024 symposium will be the sixth annual and, in response to requests from previous attendees, will focus on GLP-1 Agonists; LDL cholesterol; Lp(a); and the cardiovascular effects of marijuana. Each presentation addresses a current topic in cardiovascular disease prevention and/or management. Presenters address current guidelines and practice changes, new therapies and the latest developments in cardiovascular health care. The evening also includes a question-and-answer session with the expert presenters, allowing the audience to clarify their learning and ask questions relevant to their daily practice.

Meet the Faculty
A photograph of Elizabeth Tuohy, MD

Elizabeth Tuohy, MD

Medical Director, Heart Disease Prevention Clinic | Allina Health Minneapolis Heart Institute - St. Paul

An image of Dr. Michael Miedema

Michael Miedema, MD, MPH

Director, Cardiovascular Prevention | Allina Health Minneapolis Heart Institute
Director, Nolan Family Center for Cardiovascular Health | Minneapolis Heart Institute Foundation

A photograph of Carolyn Wambach, PharmD

Carolyn Wambach, PharmD

GLP-1 Clinical Pharmacist | Allina Health 

A photograph of Susan White, RDN

Susan White, RDN, LD

Administrative Lead & Clinical Dietician, Preventive Cardiology | Allina Health Minneapolis Heart Institute

A photograph of Ambareesh Bajpai, MD

Ambareesh Bajpai, MD

Cardiologist | Allina Health Minneapolis Heart Institute - St. Paul

An image of Dr. Felipe Martignoni

Felipe Martignoni, MD

Cardiovascular Disease Prevention Fellow, Nolan Family Center for Cardiovascular Health | Minneapolis Heart Institute Foundation

Agenda

5:00pm-6:00pm Registration, Buffet Dinner & Exhibits
6:00pm-6:10pm Welcome (Elizabeth Tuohy, MD)
6:10pm-6:40pm Addressing the Interest in GLP-1 RAs (Michael Miedema, MD, MPH; Carolyn Wambach, PharmD; Susan White, RDN)
6:40pm-7:00pm LDL Cholesterol - How Low Should We Go? (Ambareesh Bajpai, MD)
7:00pm-7:20pm Lipoprotein(a) and Cardiovascular Disease (Elizabeth Tuohy, MD)
7:20pm-7:40pm How Does Marijuana Impact Cardiovascular Health? (Felipe Martignoni, MD)
7:40pm-8:00pm Expert Roundtable (Moderated by Elizabeth Tuohy, MD)
8:00pm-8:30pm Exhibits

Accreditation

Allina Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Allina Health designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is designed to meet the Minnesota Board of Nursing continuing education requirements for 2.0 hours of credit.  

 

Learning Objectives

  1. Discuss the evidence regarding using GLP-1 agonists in cardiovascular disease risk management.
  2. Name three considerations for LDL cholesterol lowering treatments.
  3. Recall current information on the role of LP(a) in cardiovascular disease prevention.
  4. List the effects of marijuana on cardiac health.

Thank You Exhibitors!

Abbott Kiniksa Pharmaceuticals 
Alnylam Pharmaceuticals Lexicon Pharmaceuticals, Inc. 
Amgen Merck & Co., Inc.
AstraZeneca NewAmsterdam Pharma
AtriCure, Inc. Novartis
Boehringer-Ingelheim Novo Nordisk.
Bristol-Myers Squibb Pfizer, Inc.
Edwards Lifesciences Regeneron
Esperion Therapeutics United Therapeutics
Johnson & Johnson Innovative Medicine  
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.